BioPharmSignal logoBioPharmSignal

Biotech News

Assembly Biosciences Announces Upcoming Investor Conference Presentations

Assembly Biosciences (ASMB)Assembly BiosciencesConference / presentation

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming

Related news

ASMBAssembly Biosciences2026-04-09 12:00 EST

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

ASMBAssembly Biosciences2026-10-05 14:00 EST

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

MBRXMoleculin Biotech, Inc.2026-08-27 13:01 EST

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

AVIRAtea2026-09-08 11:00 EST

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

SPROSpero Therapeutics2026-09-02 21:01 EST

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

MBRXMoleculin Biotech, Inc.2026-09-14 12:35 EST

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

View all latest news

Assembly Biosciences

Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase...

Recent company news

ASMBAssembly Biosciences2026-10-05 14:00 EST

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

ASMBAssembly Biosciences2026-09-10 20:15 EST

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

ASMBAssembly Biosciences2026-09-08 20:00 EST

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

ASMBAssembly Biosciences2026-08-13 20:00 EST

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

Stock data

Close
22.18 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States